Literature DB >> 11340574

Expression of HLA class I, beta(2)-microglobulin, TAP1 and IL-10 in Epstein-Barr virus-associated nasal NK/T-cell lymphoma: Implications for tumor immune escape mechanism.

L Shen1, A K Chiang, W P Liu, G D Li, R H Liang, G Srivastava.   

Abstract

Several mechanisms of immune escape might be in operation in Epstein-Barr virus (EBV)-associated nasal NK/T-cell lymphoma. We have previously shown the downregulation of the immunogenic EBV nuclear antigens by alternative promoter usage and the preferential selection of the deletion genotype of latent membrane protein 1 in nasal lymphoma. To understand further the strategies used for immune escape by this tumor, we examined by immunohistochemistry HLA class I expression in 15 cases using frozen sections, along with beta(2)-microglobulin and transporter associated with antigen processing 1 (TAP1) expression in 39 cases using paraffin sections. All nasal NK/T-cell lymphomas showed positive staining for HLA class I, beta(2)-microglobulin and TAP1 on most tumor cells, except for two cases (5%) in which most of the tumor cells lacked beta(2)-microglobulin staining. We next immunostained for interleukin-10 on frozen sections in 13 cases, all of which showed strong expression by most tumor cells. Transcription of human interleukin-10 but not EBV BCRF1 (viral interleukin-10) was identified by reverse transcriptase-polymerase chain reaction in these nasal NK/T-cell lymphomas. Overall, our data suggest that global downregulation of HLA class I or TAP1 rarely accounts for the ability of nasal NK/T-cell lymphoma to evade immunosurveillance and that other immune escape mechanisms may be operating in nasal NK/T-cell lymphoma, such as production of interleukin-10 to suppress the local immune response. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11340574     DOI: 10.1002/1097-0215(20010601)92:5<692::aid-ijc1237>3.0.co;2-z

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-cell lymphoma.

Authors:  Lijun Shen; Anthony C T Liang; Liwei Lu; Wing Yan Au; Yok-Lam Kwong; Raymond H S Liang; Gopesh Srivastava
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).

Authors:  Takashi Sasayama; Satoshi Nakamizo; Masamitsu Nishihara; Atsufumi Kawamura; Hirotomo Tanaka; Katsu Mizukawa; Shigeru Miyake; Masaaki Taniguchi; Kohkichi Hosoda; Eiji Kohmura
Journal:  Neuro Oncol       Date:  2011-12-12       Impact factor: 12.300

3.  Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.

Authors:  Kie-Kyon Huang; Vikrant Kumar; Kalpana Ramnarayanan; Deniz Demircioglu; Zhisheng Her; Raghav Sundar; Xuewen Ong; Zul Fazreen Bin Adam Isa; Manjie Xing; Angie Lay-Keng Tan; David Wai Meng Tai; Su Pin Choo; Weiwei Zhai; Jia Qi Lim; Meghna Das Thakur; Luciana Molinero; Edward Cha; Marcella Fasso; Monica Niger; Filippo Pietrantonio; Jeeyun Lee; Anand D Jeyasekharan; Aditi Qamra; Radhika Patnala; Arne Fabritius; Mark De Simone; Joe Yeong; Cedric Chuan Young Ng; Sun Young Rha; Yukiya Narita; Kei Muro; Yu Amanda Guo; Anders Jacobsen Skanderup; Jimmy Bok Yan So; Wei Peng Yong; Qingfeng Chen; Jonathan Göke; Patrick Tan
Journal:  Gut       Date:  2021-08-25       Impact factor: 31.793

4.  Molecular pathology of primary intraocular lymphoma.

Authors:  Chi-Chao Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2003

Review 5.  Diagnosis and treatment of Epstein-Barr virus-associated natural killer cell lymphoproliferative disease.

Authors:  Keisei Kawa
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

Review 6.  Nasal NK/T-cell lymphoma: epidemiology and pathogenesis.

Authors:  Katsuyuki Aozasa; Tetsuya Takakuwa; Tadashi Hongyo; Woo-Ick Yang
Journal:  Int J Hematol       Date:  2008-02-08       Impact factor: 2.490

7.  Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy.

Authors:  Hua Wang; Liang Wang; ZhiJun Wuxiao; HuiQiang Huang; WenQi Jiang; ZhiMing Li; Yue Lu; ZhongJun Xia
Journal:  Onco Targets Ther       Date:  2015-09-14       Impact factor: 4.147

8.  Mouse bone marrow-derived mesenchymal stem cells inhibit leukemia/lymphoma cell proliferation in vitro and in a mouse model of allogeneic bone marrow transplant.

Authors:  Ningxia Song; Lei Gao; Huiying Qiu; Chongmei Huang; Hui Cheng; Hong Zhou; Shuqing Lv; Li Chen; Jianmin Wang
Journal:  Int J Mol Med       Date:  2015-04-21       Impact factor: 4.101

Review 9.  Updating targets for natural killer/T-cell lymphoma immunotherapy.

Authors:  Weili Xue; Mingzhi Zhang
Journal:  Cancer Biol Med       Date:  2021-02-15       Impact factor: 4.248

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.